alendronate has been researched along with atorvastatin in 9 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bartosová, L; Cermáková, E; Cibicek, N; Cibicková, L; Jun, D; Micuda, S; Palicka, V | 1 |
| Agnew-Blais, J; Choudhry, NK; Parker, RM; Shekelle, P; Shrank, WH; Wolf, MS | 1 |
| Akiyoshi, T; Anami, S; Matsuyama, K; Matzno, S; Nakabayashi, T; Nishiguchi, T | 1 |
| Alencar, NM; Benevides, NM; Goes, P; Lima, V; Melo, IM; Ribeiro, RA; Silva, LM | 1 |
| Chatterjee, A; Garg, V; Kanoriya, D; Manohar, B; Pradeep, AR; Singhal, S | 1 |
| Kulińska, E; Laudy, AE; Tyski, S | 1 |
| Shu, L; Tang, X; Xiong, Z; Yi, P; Zhang, C | 1 |
2 review(s) available for alendronate and atorvastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Meta-Analysis of the Efficacy and Safety of Alendronate Combined with Atorvastatin in the Treatment of Osteoporosis in Diabetes Mellitus.
Topics: Alendronate; Alkaline Phosphatase; Atorvastatin; Bone Density; Bone Density Conservation Agents; Diabetes Mellitus; Female; Humans; Osteocalcin; Osteoporosis; Osteoporosis, Postmenopausal | 2022 |
1 trial(s) available for alendronate and atorvastatin
| Article | Year |
|---|---|
Comparative evaluation of subgingivally delivered 1% alendronate versus 1.2% atorvastatin gel in treatment of chronic periodontitis: a randomized placebo-controlled clinical trial.
Topics: Adult; Alendronate; Atorvastatin; Chronic Periodontitis; Double-Blind Method; Female; Follow-Up Studies; Gels; Humans; Male; Middle Aged | 2017 |
6 other study(ies) available for alendronate and atorvastatin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Differential effects of statins and alendronate on cholinesterases in serum and brain of rats.
Topics: Alendronate; Animals; Atorvastatin; Bone Density Conservation Agents; Brain; Butyrylcholinesterase; Cholinesterases; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Pyrroles; Rats; Rats, Wistar; Simvastatin | 2007 |
Variability in pharmacy interpretations of physician prescriptions.
Topics: Alendronate; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Bone Density Conservation Agents; Comprehension; Contraindications; Drug Information Services; Drug Labeling; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Education, Pharmacy; Educational Status; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ibuprofen; Patient Education as Topic; Pharmaceutical Preparations; Pharmacies; Professional Competence; Pyrroles; Trimethoprim, Sulfamethoxazole Drug Combination; Urban Health Services; Writing | 2009 |
Synergistic action of statins and nitrogen-containing bisphosphonates in the development of rhabdomyolysis in L6 rat skeletal myoblasts.
Topics: Alendronate; Animals; Apoptosis; Atorvastatin; Bone Density Conservation Agents; Caspases; Cell Line; Diphosphonates; DNA Fragmentation; Drug Synergism; Enzyme Activation; Etidronic Acid; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myoblasts, Skeletal; Pyrroles; Rats; Rhabdomyolysis; Risedronic Acid | 2009 |
Low-dose combination of alendronate and atorvastatin reduces ligature-induced alveolar bone loss in rats.
Topics: Acid Phosphatase; Alanine Transaminase; Alendronate; Alkaline Phosphatase; Alveolar Bone Loss; Animals; Aspartate Aminotransferases; Atorvastatin; Body Weight; Bone Density Conservation Agents; Dental Cementum; Gingiva; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Infusions, Parenteral; Injections, Subcutaneous; Isoenzymes; Leukocyte Disorders; Leukocytes; Leukocytosis; Male; Monocytes; Neutrophils; Peroxidase; Pyrroles; Rats, Wistar; Root Resorption; Tartrate-Resistant Acid Phosphatase | 2014 |
The Impact of Efflux Pump Inhibitors on the Activity of Selected Non-Antibiotic Medicinal Products against Gram-Negative Bacteria.
Topics: Acyclovir; Alendronate; Amitriptyline; Anti-Bacterial Agents; Atorvastatin; Dipeptides; Drug Combinations; Drug Resistance, Multiple, Bacterial; Escherichia coli; Famotidine; Genes, MDR; Klebsiella pneumoniae; Magnesium Sulfate; Microbial Sensitivity Tests; Nicergoline; Pseudomonas aeruginosa; Quinolones; Salmonella; Ticlopidine | 2017 |